Show less
Morning Call: Softer dollar boosts commodities, stocks
21 September 2018 at 7:40 GMT
Morning Call: Markets stabilise as trade tensions ease
20 September 2018 at 8:28 GMT
Morning Call: Chinese shares surge as trade war rages on
19 September 2018 at 8:36 GMT
Today’s FX chart analysis - video
John J Hardy
18 September 2018 at 10:28 GMT
Morning Call: Trump hits China with tariff plan
18 September 2018 at 7:29 GMT
The week ahead in macro
Kay Van-Petersen
17 September 2018 at 8:11 GMT
Macro Monday week 38: Keep Global Macro and Carry On
Kay Van-Petersen
17 September 2018 at 8:02 GMT
Morning Call: US yield curve lifts, boosting dollar
17 September 2018 at 7:23 GMT
Technical analysis webinar – A view of the market: Larsson
Kim Cramer Larsson
12 September 2018 at 14:44 GMT
Morning Call: Chinese shares fall further
11 September 2018 at 8:36 GMT
Morning Call: USD, SEK in focus
10 September 2018 at 7:49 GMT
The week ahead in macro
Kay Van-Petersen
10 September 2018 at 7:37 GMT
Morning Call: Is Japan next?
07 September 2018 at 7:35 GMT
Video / 19 May 2014 at 10:26 GMT

Garnry: "Astra Zeneca shareholders blew it"

Peter Garnry

AstraZeneca’s stock price tumbled 14 percent on Monday morning after the company rejected Pfizer’s fourth and ‘final offer’ for a merger.

In the latest offer, Pfizer valued the company at GBP 55 per share or GBP 69.4 billion. This was reportedly too low for AstraZeneca, which had previously stated that its board would only consider an offer of at least GBP 58.85 per share.

The two companies have been embattled in merger negotiations since January. Pfizer originally expressed interest in AstraZeneca, underlying their ambition to create the world’s largest pharmaceutical company. Ian Read, Pfizer’s CEO has also stated that a merger between the two companies would help reduce labour and tax costs. Concern over large-scale layoffs has created major opposition against the merger in Europe, where AstraZeneca is based.

Under British law Pfizer has until May 26th to persuade AstraZeneca to entertain their ‘final offer’; otherwise the company will be prohibited from making another proposal for six months. During which period AstraZeneca would be under enormous pressure from shareholders to prove itself and its decision to reject Pfizer’s latest offer.

Despite the current impasse in negotiations, Pfizer has stated that it would not pursue a hostile offer targeted towards AstraZeneca’s shareholders to secure a deal.


Negotiations Timeline:

25 November, 2013 – Pfizer announces an interest in merging with AstraZeneca

5 January, 2014 – Pfizer and AstraZeneca discuss a merger in New York. Pfizer presents a GBP 55 billion offer, which AstraZeneca rejects

14 January, 2014 – AstraZeneca ends dealings with Pfizer

26 April, 2014 – Pfizer expresses interest in reinitiating merger negotiations

28 April, 2014 – Pfizer acknowledges plans for a second merger offer valuing the company at a significant premium 

2 May, 2014 – Pfizer offers GBP 63 billion, which AstraZeneca promptly rejects

6 May, 2014 – AstraZeneca release a report outlining current drugs in development and the potential for revenue to reach USD 45 billion b 2023

10 May, 2014 – Pfizer CEO, Ian Read publishes a video defending the purposed merger with AstraZeneca. Political opposition against the merger had escalated in Britain over the fear of job cuts and delayed research.

16 May, 2014 – After the market closed, Pfizer sent AstraZeneca another offer valuing the company at GBP 53.50 a share

17 May, 2014 – AstraZeneca’s board meets and formally rejects the latest offer and holds a conference call with Pfizer to discuss the short-comings of the offer

18 May, 2014 – Pfizer revises its bid to GBP 69.4 billion or GBP 55 per share, which AstraZeneca again rejects

26 May, 2014 – Pfizer’s negotiating period ends and must wait six months to renew negotiations


The Saxo Bank Group entities each provide execution-only service and access to permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on or as a result of the use of the Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. When trading through your contracting Saxo Bank Group entity will be the counterparty to any trading entered into by you. does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of ourtrading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws. Please read our disclaimers:
- Notification on Non-Independent Invetment Research
- Full disclaimer

Check your inbox for a mail from us to fully activate your profile. No mail? Have us re-send your verification mail